While toxic effects from inhibition of MMP-9 led to the failure of this treatment in various solid tumor therapies, we observed that B-ALL cells—possibly in conjunction with cytarabine—are highly sensitive to MMP-9 inhibition at lower doses, which led to reduced leukemia progression but no overt toxicity. Here, MMP9 is linked to leukemia.